Introduction
The significance of disseminated tumor cells (DTC) in the bone marrow of colorectal cancer patients is not clear. DTC are identified within the bone marrow in 17-64% of CRC patients (median 29%). [1] They are a subset of circulating tumor cells that migrate to the bone marrow and can form micrometastases. This phenomenon is mostly described in breast cancer patients. Although DTC in bone marrow occurs in a substantial percentage of cancer patients without distant or nodal metastases a large portion of them will not experience distant metastases in the future. Additionally, cancer cells in the bone marrow may be dormant for several years before re-entering circulation however such situations are very uncommon in colorectal cancer. Two meta analyzes of studies on the prognostic significance of circulating cancer cells in colorectal cancer indicated that the presence of DTC in the peripheral blood is a negative prognostic factor. [2, 3] At present, there is insufficient evidence that the presence of DTC in the bone marrow of colorectal cancer patients influences the prognosis. [4, 5, 6, 7] Such studies, especially in nondisseminated colorectal cancer (CRC), require a large number of patients and a long followup period as the median survival in radically operated colorectal cancer patients is longer than 5 years. In addition, colorectal cancer is not a homogenous disease and depending on the location of primary tumor it's understood that right-sided and left-sided cancers may have disparate biology and different prognosis. [8, 9, 10, 11] Therefore this study concentrated on malignancies arising from the left colon and rectum, with locally advanced cancer being the main area of interest.
The aim of this study was to analyze the relationship between the presence of DTC in bone marrow with the tumor characteristics, cancer progression and survival in left-sided colorectal cancer.
Patients and Methods
The study involved a group of 91 colorectal cancer patients treated in a single institution between 2007 and 2012. Only patients with tumors located in the rectum or left colon were included. The term left colon was defined as a section of colon distal to the left 1/3 of the transverse colon. The inclusion criteria were age over 18, histologically confirmed cancer and electively performed surgical procedure. Patients with synchronous right-sided colon cancer or patients with a history of other neoplastic diseases were excluded. None of the colon cancer patients received preoperative chemotherapy, while 5 of the rectal cancer patients received preoperative radiotherapy and 2 preoperative chemoradiotherapy. The group was composed of 42 women and 49 men with the mean age of 64.7 (SD 10.2). Cancer stage in analyzed patients was the following: T1-2 pts, T2-16 pts, T3-60 pts, T4-13 pts, N0-42 pts, N1-20 pts, N2-25 pts, Nx-4 pts, M0-67 pts, M1-24 pts. The clinicopathological characteristics of the patients are summarized in Table 1 .
A bone marrow biopsy from the posterior superior iliac spine was performed on the day of surgery after the induction of general anesthesia. A 5ml sample of the bone marrow was collected into plastic tubes containing EDTA (ethylenediaminetetraacetic acid). Table 2 ). The prevalence of DTC was not related to the depth of infiltration (T feature) and was similar in T1-2 and T4 patients. There was no statistically significant difference between the prevalence of DTC in N-and N+ patients. Patients with and without distant metastasis also had similar rates of DTC detection in the bone marrow.
The prevalence of DTC in the bone marrow of patients with TNM stages I-IV was similar, with a slightly lower prevalence in Stage IV patients. The presence of DTC in the bone marrow was not related to either the tumor grade or the resection radicality.
The number of patients who received preoperative treatment was low, however, 5 of the rectal cancer patients received preoperative radiotherapy, and 3 of those had DTC in their bone marrow. Two rectal cancer patients received preoperative chemoradiotherapy and five weeks after treatment completion both of them were found to harbor DTC in their bone marrow.
All the patients were followed-up for at least five years. The 5-year survival rate for the DTC positive patients was 59.5%, while for the DTC negative patients it was 53%. The difference between groups was not statistically significant. (Figure1) . Because DTC could, in theory, be a source of distant metastasis and cancer progression, further analysis of patients in stages II and III was performed. Stage IV patients were excluded because they already had disseminated disease, while Stage I patients were excluded because of a very low probability of tumor progression. In the group with stage II and III patients, the 5-year survival rates were 59.2% and 76% for DTC negative and positive patients respectively (Figure 2a ). Even though the difference was almost 17% in favor of DTC positive patients, it was not statistically significant. The proportion of stages II and III in DTC negative and positive groups was 14/13 and 12/13 respectively. The mean age of DTC negative patients was 63 years while in DTC positive group 65.3 years. The trend towards the better survival of DTC positive patients was also marked in stages II and III separately, however, due to the small number of patients, it did not reach statistical significance (Figure 2b,2c) .
Disease recurrence was assessed in stages II and III. Metastatic disease was diagnosed in 13 patients (25%). Sites of metastasis were varied, with the prevalence of liver metastasis (7 of 13 patients). In the DTC negative group, 10 cases were observed, while in the DTC positive group only 3 cases were observed. The difference between the occurrence of distant metastasis between the mentioned above groups was found to be statistically significant (p=0.0375).
Discussion
This study was started in 2007 and the authors decided to use methodology already established for gastric cancer in colorectal cancer patients. [12] The preliminary results were not published earlier as such a study requires long term follow up. At the current time point, all the patients recruited were followed for at least five years. The group of patients in this investigation was more homogenous than in other studies since only left-sided colon and rectal cancer patients were included. Most studies involved populations of colorectal cancer patients that had both left and right-sided disease or only included patients with rectal cancer.
Right-sided colon cancer has different clinical and molecular characteristics than left-sided colon and rectal cancer and it's proposed to analyze it separately in clinical and scientific studies. [13] The DTC in bone marrow were diagnosed in 46.1% of patients. The other studies reported an incidence between 10 and 63.6% [7, 14] although, the majority of studies reported it at the level between 25-40%. With the high number of epitopes of the tumor cells used and different methods of its detection (immunocytochemistry, immunomagnetic assay, RTPCR -reversetranscriptase polymerase chain reaction) there is no standard method for identifying DTC within the bone marrow. [15] The rate of detection is different with regard to the method used, even in the same study. [16, 17] The method which was used within the presented study is based on FACS (fluorescence-activated cell sorting) cell sorting and the detection of cells expressing the common epitope of cytokeratins 8,18 and 19 within the sorted population.
Therefore, this method may be more sensitive than other simpler methods as the cell population is enriched with the initial sorting.
The incidence of DTC in the bone marrow was not related to the depth of tumor infiltration, nodal involvement, nor distant metastasis. Similar observations were characterized in a German study of colon cancer patients. [16] However, in the aforementioned group of patients, over 40% had tumors located in the right-sided colon. Others supported these findings in different groups of colorectal patients, [4, 7] but there were also contrary observations. [18, 19] There is also a common opinion that the tumor grade does not influence the rate of bone marrow DTC. [4, 16] We observed no difference in the prevalence of DTC between left colon and rectal cancer patients. This is in line with other studies that demonstrated similar results. [4, 20] For colon cancer patients, neoadjuvant therapy is the exception and not the norm, but rectal cancer patients may receive preoperative radiotherapy or chemoradiotherapy according to indications. In our study, only 7 rectal cancer patients underwent preoperative treatment.
While this represents a low number, this method was not used routinely in the first study period. It was not anticipated that the short course radiotherapy would affect the DTC, however, 5 weeks of chemoradiotherapy could potentially eradicate such cells. The study on DTC in rectal cancer showed that they are identified less frequently in patients who responded to preoperative chemoradiotherapy. [21] Moreover, in a study on gastric cancer, chemotherapy was able to significantly reduce the prevalence of DTC in the bone marrow. [22] We observed only two patients who received preoperative chemoradiotherapy. After this therapy, both of them were DTC positive. This observation has no statistical power but clarifies that the preoperative treatment did not bias results in rectal cancer patients.
The overall survival at 5 years in the DTC positive group was 59.5% while for DTC negative patients it was 53%. The difference was statistically not significant, and both groups had comparable stages according to TNM classification. This observation alone was not astonishing since other studies demonstrated that the presence of DTC in bone marrow may not be a negative prognostic factor for colorectal cancer patients. This was also the conclusion of one of the meta-analyzes published in 2010, [23] however authors paid attention to the fact that the methods of DTC detection were inhomogeneous. Therefore, there is still a place for new studies that enrich the population of patients diagnosed using a specific method. For further analysis, we excluded the most advanced stage IV patients. The prognostic significance of bone marrow DTC was described in stage IV colorectal cancer, however only in patients after curative resection of liver metastasis. [24] On the other hand, others demonstrated that this phenomenon may be related to the method of detection used. [17] We could not find a study that demonstrated the prognostic significance of DTC in Stage IV colorectal cancer patients not treated with the radical resection of metastasis. In our Stage IV patients. only one had a simultaneous liver resection for metastasis. Also, stage I patients were excluded because of the very low probability of cancer progression with definitive treatment.
Other studies, especially those with low patient numbers, included stage I patients, [5] but larger studies analyzed mainly those with stage II and III disease. [4] When stages II and III were analyzed together, the 5 years survival was 76% for the patients with bone marrow DTC and 59.2% for DTC negative patients. This difference was not statistically significant. These results are contrary to a recent publication from Switzerland, where bone marrow cells were detected with the same type of pan-cytokeratin antibody, with a detection rate similar to ours in patients in stages I-III. The authors found that DTC in the bone marrow was a negative prognostic factor for survival. [25] The difference with our study was the exclusion of rectal cancer patients and that only about 40% of patients had a left-sided tumor. The cited results were also not supported by others who could not find a prognostic significance of DTC in bone marrow for colorectal cancer patients. [7, 20] In all our survival plots, there is a visible trend favoring patients with DTC in bone marrow, but without reaching statistical significance. Therefore, we tried to analyze the incidence of distant metastasis during the 5-year follow up period. In theory, the tumor cells located in the bone marrow could be the source of distant metastasis. There should be a correlation between DTC and metachronous metastasis. Such a situation has been observed in various cancers like breast, [26] prostate [27] and esophageal. [28] Surprisingly, in our study, there was statistically significantly less metachronous distant metastasis in patients with DTC in their bone marrow than in DTC negative patients. The reason for this finding may be the low number of patients however this number is not significantly lower than in the majority of similar studies with the same TNM stages. This finding may indicate that the presence of DTC in some way prevented the progression and metastasis formation. There are theories why DTC do not influence cancer progression, [29] but not about its beneficial effect. Bone marrow is a specific niche with the number of hematopoietic and immunocompetent cells and also stem cells. DTC are present during the generation and maturation of various immunocompetent cells. As was demonstrated, the generation of monocytes from hematopoietic CD34 + stem cells from the bone marrow of colon cancer patients is possible, and these cells act as antigenpresenting cells. They may present tumor-specific antigens to cytotoxic T-lymphocytes. [30] Moreover, it was demonstrated, that after in vivo exposure to blood-derived cell-associated tumor-associated antigens (TAA), BM dendritic cells were capable of inducing systemic protective T cell-mediated anti-tumor immunity upon adoptive transfer. [31] In contrast to BM, responses of lymph nodes to blood-circulating antigen were only weak. There is evidence that bone marrow-derived dendritic cells differ from peripheral blood-derived dendritic cells, but the importance of this difference is not clear. [32] Bone marrow also seems to be a preferential site for migration and/or selective retainment of memory T-cells and becomes enriched with antigen-specific memory T lymphocytes in response to virus infection or tumor development. [33, 34] Such a mechanism may be the background of the phenomenon observed in our study. DTC surrounded by immune cells may be the source of tumor-related antigens and generate an immune reaction against these antigens. Therefore, DTC may act as a kind of cancer vaccination.
In the previous observations, it has been shown that blood circulating breast cancer cells may settle in the bone marrow and spleen. In these places, antigen-presenting cells may pick-up, process and cross-present tumor-associated antigens to prime naive T lymphocytes. This may lead to generation and maturation of specific effector and also memory T cells. Particular clones of so activated cytotoxic T lymphocytes, upon contact with tumor cells, may exhibit cytotoxic activity or even control dormant cancer foci. [35] It was also proposed that small amounts of persisting tumor-associated antigens produced by dormant tumor cells from the bone marrow may contribute to the maintenance of tumor-specific and long-term memory mediated by appropriate subsets of memory T lymphocytes. [36] The presence of DTC in the bone marrow is not associated with primary tumor characteristics and seems to diminish metastasis formation in left-sided colorectal cancer. There is a trend for improved overall survival for DCT positive patients.
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